vulval Paget disease

Summary

vulval Paget disease (MONDO:0002207) is a disease and 5 clinical trials. Top therapeutic interventions include bleomycin and trastuzumab. A subtype of extramammary Paget disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vulval Paget disease
Mondo ID	MONDO:0002207
DOID	DOID:2097
NCIT	C4027
SNOMED CT	254898001
UMLS	C1275217
MedGen	266154
GARD	0023083
Anatomy (UBERON)	UBERON:0000997
Is cancer (heuristic)	no

Also known as: mammalian vulva Paget disease · Paget disease of the vulva · Paget’s disease of the vulva · Paget’s disease of vulva · vulva Paget’s disease · vulval Paget’s disease · vulvar Paget’s disease

Disease family

This is a subtype of extramammary Paget disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › Paget disease › extramammary Paget disease › vulval Paget disease

Related subtypes (2): anal Paget disease, Paget disease of the penis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06715592	PHASE2	ACTIVE_NOT_RECRUITING	ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study
NCT01427244	PHASE2	WITHDRAWN	Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget’s Disease
NCT03713203	Not specified	RECRUITING	PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget’s Disease of the Vulva (EMPV).
NCT00897442	Not specified	COMPLETED	Collecting Tumor Samples From Patients With Gynecological Tumors
NCT03900975	Not specified	COMPLETED	Vulvar Paget Disease

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BLEOMYCIN	4	1
TRASTUZUMAB	4	1